FORMULATION COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE AGENT
An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs such as Form I, Form II and Form III thereof to improve the bioavailability intended for self-emulsification upon its contact with the gastro-intestinal flui...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English Spanish |
Published |
06.12.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs such as Form I, Form II and Form III thereof to improve the bioavailability intended for self-emulsification upon its contact with the gastro-intestinal fluid. The invention also relates to a process for the preparation of oral solution containing NRC-AN-019 in an effective concentration for the better therapy against Chronic Myeloid Leukemia as BCR-ABL tyrosine kinase inhibitor and against other tumors such as head and neck cancer, prostate cancer and the like.
Una formulación farmacéutica oral que contiene una cantidad efectiva de NRCAN-019 incluyendo sus sales farmacéuticamente aceptables y polimorfos tales como Forma I, Forma II y Forma III del mismo para mejorar la biodisponibilidad destinada para auto-emulsificación al hacer contacto con el fluido gastrointestinal. La invención también se refiere a un procedimiento para la preparación de solución oral que contiene NRC-AN-019 en una concentración efectiva para la mejor terapia contra leucemia mieloide crónica como inhibidor de tirosina quinasa de BCR-ABL y contra otros tumores tales como cáncer de cabeza y cuello, cáncer de próstata y similares. |
---|---|
Bibliography: | Application Number: MX20130010160 |